Dr Antonarakis’ research focuses on drug development and clinical trial design for patients with prostate cancer, as well as cancer genetics and genomics. More specifically, he is exploring novel androgen-directed therapies, genetically targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, using germline and cancer genomics to inform precision oncology approaches.
He also has an interest in liquid biomarker development, specifically the clinical utility of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is the PI of multiple phase II and III prostate cancer trials and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the ECOG-ACRIN and Alliance Cooperative Groups, as well as the NCI Prostate Cancer Task Force and the NCCN Prostate Cancer Panel.
In 2021, he was elected into the American Society for Clinical Investigation (ASCI). He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology.
He is the author of over 410 peer-reviewed scientific articles, several book chapters, and has edited two textbooks on prostate cancer.